Posted by Michael Wonder on 07 Dec 2021
Junshi Biosciences announces two additional indications for toripalimab included in China’s National Reimbursement Drug List
3 December 2021 - The only anti-PD-1 monoclonal antibody in the NRDL for melanoma and nasopharyngeal carcinoma.
Junshi Biosciences announced today that the company’s product toripalimab continues to be included in Category B in the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021 Edition) upon negotiations, with two additional indications including the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least two lines of prior systemic therapy and patients with locally advanced or metastatic urothelial carcinoma after failure of platinum-containing chemotherapy or progressed within 12 months of neo-adjuvant or adjuvant platinum-containing chemotherapy.
